Clinical Trial Update: A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC [Phase 2]

View source ↗

Summary

A prospective, randomized Phase 2 trial evaluating transarterial chemoembolization with a triple-immunotherapy regimen (sintilimab, bevacizumab, and ipilimumab)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Tyvyt (Sintilimab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: RECRUITING